Morepen Laboratories share price today

Morepen Laboratories Ltd's share price was ₹102.31 at the close on 3 November 2026. It has been rising for 18 weeks. That is 30.9% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹34 and ₹134, and at that close it sat 68% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Morepen Laboratories Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 27 weeks in a row.

Over the last 11 years the share price moved +278% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: best operating margin in 16 quarters, highest quarterly profit in 16 quarters and highest quarterly revenue in 16 quarters.

1. Best operating margin in 16 quarters

   Operating margin was 16% in the September 2026 quarter, against 7% a year earlier.

2. Highest quarterly profit in 16 quarters

   Profit of ₹89 crore in the September 2026 quarter is the highest of the last 16 quarters.

3. Highest quarterly revenue in 16 quarters

   Revenue of ₹746 crore in the September 2026 quarter is the highest of the last 16 quarters.

For July to September 2026 (the quarter ended 30 September 2026), Morepen Laboratories reported revenue of ₹746 crore, up 81.1% from ₹412 crore a year earlier, and a profit of ₹89.0 crore, up 117.1% from ₹41.0 crore.

Morepen Laboratories results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Morepen Laboratories closed at ₹102.31 on 3 November 2026, up 115.0% from ₹47.58 a year earlier (31 October 2025) and up 100.0% over five years. Its highest weekly close since March 2016 was ₹133.70 on 1 October 2026.

Morepen Laboratories share price: then and now

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

561 weekly closes from 11 March 2016 to 3 November 2026.

3 Nov 2026: Morepen Laboratories closed at ₹102.31, down 17.0% on the week and down 23.5% on the month. Results for July to September 2026: Revenue up 81.1% and profit up 117.1% on a year earlier.

Earlier

• 18 Sep 2026: ex-date for a dividend of ₹0.20 a share, record date 19 Sep 2026.

Morepen Laboratories paid ₹0.20 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 0.20% at the ₹102.31 close on 3 November 2026. The last was a dividend of ₹0.20 a share, ex-date 18 September 2026.

Morepen Laboratories dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. Morepen Laboratories Ltd paid out 12% of its profit as dividends in FY26, and it paid a dividend in 2 of its last 13 reported years.

From the NSE corporate-actions record, read 4 November 2026.

Morepen Laboratories is on one of our India lists: Pharma stocks.

Morepen Laboratories Ltd earned ₹89.0 Cr of net profit in the Sep 2026 quarter, +117.1% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹96.0 Cr. Over 10 years profit has grown 22.1% a year on average. That is 11.9% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹41.0 Cr.

For the full year, FY26 profit was ₹96.0 Cr (−18.6% on the year before).

Why profit moved: revenue changed +81.1% on a year earlier and the margin moved +9.0 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed +127.5% and revenue +31.5%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

Morepen Laboratories Ltd reported ₹746 Cr of revenue in the Sep 2026 quarter, +81.1% on the same quarter a year earlier. That is the 4th quarter in a row with growth on the year before. Over 10 years it has grown 14.1% a year on average. The last full year, FY26, came in at ₹1,806 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹2,285 Cr.

FY26 revenue was ₹1,806 Cr, −0.3% on the year before.

Recent pace: the last four quarters grew +31.5% on average, against 14.1% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +30.1%, against +13.9% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +90.9%, against +19.7% a year (accelerating).

Morepen Laboratories Ltd's operating margin was 16.0% in the Sep 2026 quarter, 9.0 percentage points higher than the same quarter a year ago. Across 13 years it has been between 6.0% and 13.0%. The latest quarter is above every full year in that period.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +9.0 percentage points on the year while gross margin changed +13.0 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

Over the last 3 years, 44% of Morepen Laboratories Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 it brought in ₹33.0 Cr of operating cash against ₹96.0 Cr of profit. After ₹54.0 Cr of spending on assets, free cash was −₹21.0 Cr: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 44% of profit came in as cash: the cash cycle got 13 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page.

What to look at next: less of the profit turns into cash than it should, and the cash cycle is 13 days longer. The next section looks at where the cash is stuck.

Morepen Laboratories Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 53 days in FY26, up from 40 days in FY21. It spent ₹349 Cr on assets over the last 3 years. Customers take 67 days to pay, and stock sits for 88 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹1,806 Cr, each day of that cycle ties up about ₹4.9 Cr, so roughly ₹262 Cr is tied up in the business at any time.

FY26: customers took 67 days to pay and stock sat for 88 days, about 2.9 months of sales sitting as stock, for a full cycle of 53 days, longer than FY21's 40.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 88 days. Customers pay about 67 days after that. Suppliers are paid at 103 days. Together that makes the 53-day cycle.

Spending on assets: ₹349 Cr over the last 3 years, against ₹98.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹22.0 Cr (FY26): assets paid for that are not earning yet.

In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit.

Morepen Laboratories Ltd's P/E is 29.8×, in the middle of its own history: higher than 45% of past readings. Its usual P/E (the middle reading) is 30.8×, over 10 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.